Neurobiologia e Patologia Molecolare e Cellulare

Responsabile

Prof. Michele Zoli (PO)

Personale strutturato, compreso quello tecnico

Prof. Serena Carra (PA)
Prof. Giulia Curia (PA)
Prof. Anna Valeria Vergoni (PA)
Dott. Antonietta Vilella (RTDa)
​Dott. Giuseppina Leo (PTA)

Assegnisti, Dottorandi, Borsisti, Contrattisti

Letizia Manca, Eleonora Daini, Miriam Cavagnini, Laura Mediani, Federica F. Morelli, Tatiana Tiago

 

Obiettivi dell'attività di ricerca

L’attività scientifica si concentra su 4 linee di ricerca principali: 

a) Funzioni dei chaperoni molecolari, quali le proteine da shock termico HSPB8-BAG3 ed HSPB2-HSPB3 e loro implicazione in malattie neurodegenerative e neuromuscolari caratterizzate da accumulo di aggregati di RNA e proteine; 

b) Riparazione anatomo-funzionale del cervello e scomparsa delle crisi epilettiche attraverso l'uso di bioibridi funzionali impiantati in modelli animali di patologie neurologiche e alterazioni anatomo-molecolari ed elettrofisiologiche dell'eccitabilità neuronale nei modelli animali di epilessia.; 

c) Fisiopatologia dei sottotipi dei recettori nicotinici per l’acetilcolina neuronali con particolare attenzione ai meccanismi molecolari e cellulari della dipendenza da nicotina e la neuroprotezione; d) Meccanismi epigenetici della plasticità neuronale.

 

Collaborazioni

 

  • Prof. Simon Alberti, Technische Universität Dresden, Center for Molecular and Cellular Bioengineering (CMCB), Biotechnology Center (BIOTEC), Dresda, Germania
  • Prof. Angelo Poletti, Sezione di Biomedicina e Endocrinologia, Dipartimento di Scienze Farmacologiche e Biomolecolari, Centro di Eccellenza sulle Malattie Neurodegenerative, Universita' degli Studi di Milano
  • Dott.ssa Cristina Cereda, Centro di Genomica e post-Genomica, IRCCS Mondino Pavia 
  • Prof. Paola Sacerdote, Dipartimento di Farmacologia, chemioterapia e farmacologia medica, Universita' degli Studi di Milano
  • Dott. Vincenzo di Marzo, CRN, Istituto di Cibernetica, CNR, Pozzuoli (Na)
  • Prof. Harm H. Kampinga, Department of Cellular Biology, University Medical Center Groningen, University of Groningen
  • Dott. Wilbert Boelens, Assistant Professor, Laboratory of Experimental Radiotherapy, Nijmegen Centre for Molecular Life Sciences
  • Prof. Andrea Becchetti, Università di Milano-Bicocca, Milano, Italia.
  • Dott. Francesco Bellini, Eurokleis, Roma, Italia.
  • Prof. Juan Manuel Corchado, Fundacion Instituto de Estudios de Ciencias de la salud de Castilla Y Leon, Salamanca, Spagna.
  • Dott. Ilaria Decimo, Università di Verona, Verona, Italia.
  • Dott. Laura Ewell - University of Bonn, Bonn, Germany.
  • Prof. Silvana Franceschetti, Istituto Nazionale Neurologico “Carlo Besta”, Milano, Italia.
  • Dott. Miao He - Institute of Brain Sciences, Fudan University, Shanghai, China.
  • Dott. Hadi Heidari, University of Glasgow, Glasgow, UK.
  • Prof. Jari Hyttinen, Tampere University of Technology, Tampere, Finlandia.
  • Prof. Daniele Ielmini, Politecnico di Milano, Milano, Italia.
  • Dott. Carlo Ierna, Radboud University, Nimega, Olanda.
  • Dott. Massimo Mantegazza, Institut de Pharmacologie Moléculaire et Cellulaire (IPMC), CNRS and Université Côte d'Azur, Valbonne-Sophia Antipolis, Francia.
  • Dott. Cristina Marchetti, European Brain Research Institute (EBRI) Rita Levi Montalcini, Roma, Italia.
  • Prof. Farshad Moradi, Aarhus Universitet, Aarhus, Danimarca.
  • Dott. Andrea Nicolai, Design Entrepreneurship Institute, Brussels, Belgio.
  • Dott. Gemma Palazzolo, Istituto Italiano di Tecnologia, Genova, Italia.
  • Dott. Gabriella Panuccio, Istituto Italiano di Tecnologia, Genova, Italia.
  • Dott. Teresa Serrano, Agencia Estatal Consejo Superior de Investigaciones Cientificas, Madrid, Spagna.
  • Prof. Maria R Picciotto, Department of Psychiatry, Yale University, New Haven
  • Dott. Alban De Kerchove D’Exaerde, Université Libre de Bruxelles, Bruxelles
  • Prof. Pierluigi Nicotera, German Centre for Neurodegenerative Diseases (DZNE), Bonn
  • Prof. Laurent Schaeffer, Institut NeuroMyoGène,, Lyon
  • Dott. Giordano Lippi, Scripps Clinic, La Jolla, California, USA
  • Dott. Uwe Maskos, Institut Pasteur, Paris, France
  •  

    Fondi di ricerca

  • 2019-2023 Horizon 2020 FETPROACT2018-824164 “Hybrid Enhanced Regenerative Medicine Systems”, PI: Curia
  • 2019-2021 Agenzia di Ricerca per la Sclerosi Laterale Amiotrofica (AriSLA). PI: Carra S; Partners: Poletti A, Cereda C.
  • 2017-2020 AIFA; PI: Mandrioli J; Partner: Carra S.; D'Amico R.; Chiò A.; Silani V.; Ceroni M.; Simone I.L.; Riva N.; Sabatelli M.; Monsurrò M.R.; Sorarù G.; Poletti A.; Cereda C.; Bonetto V.
  • 2017-2019 Ministero degli Affari Esteri e della Cooperazione Internazionale; PI: Carra S; Israeli PI: Ben-Zvi A.
  • 2016-2019 PRIN Coordinator: Poletti A.; partners: Carra S; Carrì MT; Cozzolino M; Crosio C; Ratti A; Chiò A.
  • 2016-2019 JPco-fuND, PI: Alberti S; partners: Kaganovich D, Carra S, Sterneckert J, Poletti A, Dantuma N, Aguzzi A. 
  • 2016-2018 Ministero degli Affari Esteri e della Cooperazione Internazionale; Italian PI: Carra S; Israeli PI : Kaganovich D.
  • 2015-2018 Telethon Foundation, GGP15001, PI: Carra S
  • 2015-2018 Agenzia di Ricerca per la Sclerosi Laterale Amiotrofica (AriSLA). PI: Carra S; Partners: Poletti A, Cereda C, Mandrioli J. 
  • 2015-2017 Cariplo Foundation; PI: Poletti A.; Partner: Carra S.; Provenzani A.
  • 2012-2014 Association Française contre les Myopathies (AFM) (Carra, PI
  • 2012-2013 Telethon Exploratory Project (Carra, PI)
  • 2011-2014 MIUR/Rita Levi Montalcini (Carra, PI)
  • 2017-2019: UNIMORE/FAR2016 Dipartimentale “Characterization of epileptic seizures and seizure susceptibility in an animal model of Alzheimer's disease” (Curia, PI).
  • 2013-2014: Alzheimer’s Association (USA) “Learning from epilepsy to understand Alzheimer's disease” (Curia, collaboratore).
  • 2012-2015: Fondazione Telethon (Italia) “The role of neuronal nicotinic receptors in the pathogenesis of autosomal dominant nocturnal frontal lobe epilepsy: a study on wild-type and conditional transgenic mice expressing the beta2-V287L subunit” (Curia, collaboratore).
  • 2012-2013: Fondazione Pierfranco e Luisa Mariani (Italia) “Novel treatment for a genetic drug-resistant epileptic encephalopathy of infancy: virus delivered RNA interference in an animal model of Dravet syndrome” (Curia, PI)
  • 2010-2014: Ministero per l’Istruzione, l’Università e la Ricerca (MIUR, Italia). Rientro dei Cervelli “Neurophysiological and molecular-anatomic alterations of hippocampal and parahippocampal networks in a mouse model of Fragile X syndrome” (Curia, PI)
  • 2011-2013: MIUR FIRB “Structure and function of the nicotinic acetylcholine receptors (nAChR) in the neural systems of positive and negative reinforcement, the mesolimbic and habenulo-interpeduncular systems” (Zoli PI)
  • 2011-2014: Italian Ministry of Health “Role of alpha6 nicotinic receptor subunit in tobacco dependence” Zoli (PI)
  • 2010-2013: ERANET “Modeling human polymorphisms for nicotine addiction in mice” (Zoli, CoPI)
  •  

     

    Pubblicazioni più significative sull’argomento

  • Meister-Broekema M, Freilich R, Jagadeesan C, Rauch JN, Bengoechea R, Motley WW, Kuiper EFE, Minoia M, Furtado GV, van Waarde MAWH, Bird SJ, Rebelo A, Zuchner S, Pytel P, Scherer SS, Morelli FF, Carra S, Weihl CC, Bergink S, Gestwicki JE, Kampinga HH. Myopathy associated BAG3 mutations lead to protein aggregation by stalling Hsp70 networks. Nat Commun. 2018 Dec 17;9(1):5342. doi: 10.1038/s41467-018-07718-5.
  • Alberti S and Carra S. Quality Control of Membraneless Organelles. J. Mol. Biol. 2018 doi.org/10.1016/j.jmb.2018.05.013. Review
  • Morelli FF, Verbeek S, Bertacchini J, Vinet J, Mediani L, Marmiroli S, Cenacchi G, Nasi M, De Biasi S, Brunsting JF, Lammerding J, Pegoraro E, Angelini C, Tupler R, Alberti S, Carra S. Aberrant compartment formation by HSPB2 mislocalizes lamin A and compromises nuclear integrity and function. Cell Rep. 2017 Aug 29;20(9):2100-2115. doi: 10.1016/j.celrep.2017.08.018. 
  • Cristofani R, Crippa V, Rusmini P, Cicardi ME, Meroni M, Giorgetti E, Sala G, Galbiati M, Piccolella M, Messi E, Ferrarese C, Carra S, Poletti A. Inhibition of retrograde transport modulates misfolded protein accumulation and clearance in motoneuron diseases. Autophagy. 2017 Apr 12:0. doi: 10.1080/15548627.2017.1308985. 
  • Mateju D, Franzmann TM, Patel A, Kopach A, Boczek EE, Maharana S, Lee HO, Carra S, Hyman AA, Alberti S. An aberrant phase transition of stress granules triggered by misfolded protein and prevented by chaperone function. EMBO J. 2017 Apr 4. pii: e201695957. doi: 10.15252/embj.201695957.
  • Ganassi M, Mateju D, Bigi I, Mediani L, Poser I, Lee HO, Seguin SJ, Morelli FF, Vinet J, Leo G, Pansarasa O, Cereda C, Poletti A, Alberti S, Carra S. A surveillance function of the HSPB8-BAG3-HSP70 chaperone complex ensures stress granule integrity and dynamism. Mol Cell. 2016 Aug 25. pii: S1097-2765(16)30374-4. doi: 10.1016/j.molcel.2016.07.021.
  • Crippa V, Cicardi ME, Ramesh N, Seguin SJ, Ganassi M, Bigi I, Diacci C, Zelotti E, Baratashvili M, Gregory JM, Dobson CM, Cereda C, Pandey UB, Poletti A, Carra S. The Chaperone HSPB8 Reduces the Accumulation of Truncated TDP-43 Species in Cells and Protects Against TDP-43-Mediated Toxicity. Hum Mol Genet. 2016 Jul 27. pii: ddw232.
  • Vos MJ, Carra S, Kanon B, Bosveld F, Klauke K, Sibon OC, Kampinga HH. Specific protein homeostatic functions of small heat-shock proteins increase lifespan. Aging Cell. 2016. 15(2):217-26.
  • Minoia M, Boncoraglio A, Vinet J, Morelli FF, Brunsting JF, Poletti A, Krom S, Reits E, Kampinga HH, Carra S. BAG3 induces the sequestration of proteasomal clients into cytoplasmic puncta: implication for a proteasome-to-autophagy switch. Autophagy. 2014. 10(9):1603-21.
  • Seguin SJ, Morelli FF, Vinet J, Amore D, De Biasi S, Poletti A, Rubinsztein DC, Carra S. Inhibition of autophagy, lysosome and VCP function impairs stress granule assembly. Cell Death Differ. 2014. 21(12):1838-51.
  • Carra S, Rusmini P, Crippa V, Giorgetti E, Boncoraglio A, Cristofani R, Naujock M, Meister M, Minoia M, Kampinga HH and Poletti A. Different anti-aggregation and pro-degradative functions of the members of the mammalian sHSP family in neurological disorders. Phil. Trans. R. Soc. B, accepted.
  • Boncoraglio A, Minoia M, Carra S.The family of mammalian small heat shock proteins (HSPBs): Implications in protein deposit diseases and motor neuropathies. Int J Biochem Cell Biol. 2012 Mar 28.
  • Carra S, Crippa V, Rusmini P, Boncoraglio A, Minoia M, Giorgetti E, Kampinga HH, Poletti A. Alteration of protein folding and degradation in motor neuron diseases: Implications and protective functions of small heat shock proteins. Prog Neurobiol. 2011
  • Seidel K, Vinet J, den Dunnen WFA, Brunt ER, Meister M, Boncoraglio A, Zijlstra MP, Boddeke HWGM, Rüb U, Kampinga HH and Carra S. The HSPB8-BAG3 chaperone complex is upregulated in astrocytes in the human brain affected by protein aggregation diseases. Neuropath appl Neurobiol, 2011 Jun 23. doi: 10.1111/j.1365-2990.2011.01198.x.
  • Hishiya A, Salman MN, Carra S, Kampinga HH and Takayama S. BAG3 directly interacts with mutated alphaB-crystallin to suppress its aggregation and toxicity. PLOS ONE, 2011 Mar 15;6(3):e16828.
  • Lippi G, Fernandes CC, Ewell LA, John D, Romoli B, Curia G, Taylor SR, Frady EP, Jensen AB, Liu JC, Chaabane MM, Belal C, Nathanson JL, Zoli M, Leutgeb JK, Biagini G, Yeo JW, Berg DK. MicroRNA-101 regulates multiple development programs to constrain excitation in adult neural networks. Neuron92(6):1337-1351, 2016.
  • Curia G, Eastman CL, Miller JW, D’Ambrosio R. Chapter 10. Modeling post-traumatic epilepsy for therapy development. In: Translational research in traumatic brain injury. Edited by: Laskowitz D and Grant G. Frontiers in Neuroscience and CRC Press. 57, pp 219-238, 2015.
  • Curia G, Lucchi C, Vinet J, Gualtieri F, Marinelli C, Torsello A, Costantino L, Biagini G. Pathophysiogenesis of mesial temporal lobe epilepsy: is prevention of damage antiepileptogenic? Current Medicinal Chemistry21(6):663-688, 2014.
  • Curia G, Gualtieri F, Bartolomeo R, Vezzali R, Biagini G. Resilience to audiogenic seizures is associated with p-ERK1/2 dephosphorylation in the subiculum of Fmr1 knockout mice. Frontiers in Cellular Neuroscience7:46, 2013.
  • Eastman CL, Verley DR, Fender JS, Stewart TH, Nov E, Curia G, D’Ambrosio R. Antiepileptic and Antiepileptogenic performance of Carisbamate after head injury in the rat: blind and randomized studies. JPET336(3):779-790, 2011.
  • Curia G, Levitt M, Fender JS, Miller JW, Ojemann J, D’Ambrosio R. Impact of injury location and severity on posttraumatic epilepsy in the rat: role of frontal neocortex. Cerebral Cortex21(7):1574-1592, 2011.
  • Mantegazza M, Curia G, Biagini G, Ragsdale DS, Avoli M. Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders. The Lancet Neurology9(4):413-424, 2010.
  • Curia G, Papouin T, Seguela P, Avoli M. Downregulation of tonic GABAergic inhibition in a mouse model of Fragile X syndrome. Cerebral Cortex19(7):1515-1520, 2009.
  • Curia G, Longo D, Biagini G, Jones RSG, Avoli M. The pilocarpine model of temporal lobe epilepsy. J Neurosci Methods172(2):143-157, 2008.
  • Curia G, Aracri P, Colombo E, Scalmani P, Mantegazza M, Avanzini G, Franceschetti S. Phosphorilation of sodium channels mediated by protein kinase-C modulates inhibition by topiramate of tetrodotoxin-sensitive transient sodium current. British J Pharmacology150(6):792-797, 2007.
  • Aridon P, Marini C, Di Resta C, Brilli E, De Fusco M, Politi F, Parrini E, Manfredi I, Pisano T, Pruna D, Curia G, Cianchetti C, Pasqualetti M, Becchetti A, Guerrini R, Casari G. Increased sensitivity of the neuronal nicotinic receptor alpha 2 subunit causes familial epilepsy with nocturnal wandering and ictal fear. Am J Hum Genet79(2):342-350, 2006.
  • Rigillo G, Vilella A, Benatti C, Schaeffer L, Brunello N, Blom JMC, Zoli M, Tascedda F (2018) LPS-induced histone H3 phospho(Ser10)-acetylation(Lys14) regulates neuronal and microglial neuroinflammatory response.Brain Behav Immun. 2018 Nov;74:277-290
  • Bertolini A, Tacchi R, Vergoni AV. (2009)Brain effects of melanocortins.Pharmacol Res. 59(1):13-47.
  • Tosi G, Costantino L, Rivasi F, Ruozi B, Leo E, Vergoni AV, Tacchi R, Bertolini A, Vandelli MA, Forni F. (2007) Targeting the central nervous system: in vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123.J Control Release122(1):1-9.
  • Tosi G, Vergoni AV, Ruozi B, Bondioli L, Badiali L, Rivasi F, Costantino L, Forni F, Vandelli M (2010) Sialic acid and glycopeptides conjugated PLGA nanoparticles for central nervous system targeting: In vivo pharmacological evidence and biodistribution.J Control Release. 145(1):49-57. 
  • De Backer JF, Monlezun S, Detraux B, Gazan A, Vanopdenbosch L, Cheron J, Cannazza G, Valverde S, Cantacorps L, Nassar M, Venance L, Valverde O, Faure P, Zoli M, De Backer O, Gall D, Schiffmann SN, de Kerchove d'Exaerde A. Deletion of Maged1 in mice abolishes locomotor and reinforcing effects of cocaine.EMBO Rep. 2018 Jul 12. pii: e45089. doi: 10.15252/embr.201745089.
  • Maestrini E, Cameli C, Bacchelli E, De Paola M, Giucastro G, Cifiello S, Collo G, Cainazzo M, Pini L, Zoli M (2018) Genetic variation in CHRNA7 and CHRFAM7A is associated with nicotine dependence and response to varenicline treatment. Eur J Hum Genet, 26(12):1824-1831
  • Giordani M, Berto M, Di Lauro M, Bortolotti CA, Zoli M, Biscarini F (2017) Specific Dopamine Sensing Based on Short-Term Plasticity Behavior of a Whole Organic Artificial Synapse. ACS Sens. 2(12):1756-1760. doi: 10.1021/acssensors.7b00542.
  • Bellei E, Vilella A, Monari E, Bergamini S, Tomasi A, Cuoghi A, Guerzoni S, Manca L, Zoli M, Pini LA (2017) Serum protein changes in a rat model of chronic pain show a correlation between animal and humans. Sci Rep, 7:41723.
  • Mapelli J, Gandolfi D, Vilella A,Zoli M, Bigiani A (2016) Heterosynaptic GABAergic plasticity bidirectionally driven by the activity of pre- and postsynaptic NMDA receptors.Proc Natl Acad Sci USA113(35):9898-9903.
  • Vilella A, Tosi G, Grabrucker AM, Ruozi B, Belletti D, Vandelli MA, Boeckers TM, Forni F,Zoli M (2014) Insight on the fate of CNS-targeted nanoparticles. Part I: Rab5-dependent cell-specific uptake and distribution.J Control Release 174:195-201.
  • Tosi G, Vilella A, Chhabra R, Schmeisser MJ, Boeckers TM, Ruozi B, Vandelli MA, Forni F, Zoli M, Grabrucker AM (2014) Insight on the fate  of CNS-targeted nanoparticles . Part II:  Intercellular neuronal cell-to-cell transport .J Control Release 177:96-107. 
  • Lippi G, Steinert JR, Marczylo EL, D'Oro S, Fiore R, Forsythe ID, Schratt G, Zoli M, Nicotera P, Young KW (2011) Targeting of the Arpc3 actin nucleation factor by miR-29a/b regulates dendritic spine morphology. J Cell Biol 194:889-904.
  • Ziviani E*, Lippi G*, Bano D, Munarriz E, Guiducci S, Zoli M, Young KW, Nicotera P. (2011) Ryanodine receptor-2 upregulation and nicotine-mediated plasticity. EMBO J 30(1):194-204. *Equal contribution.
  • Gotti C*, Guiducci S*, Tedesco V, Corbioli S, Zanetti L, Moretti M, Zanardi A, Rimondini R, Mugnaini M, Clementi F, Chiamulera C, Zoli M. (2010) Nicotinic acetylcholine receptors in the mesolimbic pathway: primary role of ventral tegmental area alpha6beta2* receptors in mediating systemic nicotine effects on dopamine release, locomotion, and reinforcement. J Neurosci 30:5311-5325. *Equal contribution.
  • Durieux P, Bearzatto B, Guiducci S, Buch T, Waisman A, Zoli M, Schiffmann SN, de Kerchove d’Exaerde A (2009) D2R–striatopallidal neurons inhibit both locomotor and drug reward processes. Nature Neurosci, .
  • Grady SR*, Moretti M*, Zoli M*, Marks MJ, Zanardi A, Pucci L, Clementi F, Gotti C (2009) Rodent habenulo-interpeduncular pathway expresses a large variety of uncommon nachr subtypes, but only the {alpha}3{beta}4 and {alpha}3{beta}3{beta}4 subtypes mediate acetylcholine release. J Neurosci 29: 2272-2282. *Equal contribution.
  • Zanardi A, Ferrari R, Leo G, Maskos U, Changeux JP, Zoli M. (2007) Loss of high-affinity nicotinic receptors increases the vulnerability to excitotoxic lesion and decreases the positive effects of an enriched environment. FASEB J. 21(14):4028-4037
  • Gotti C, Zoli M, Clementi F (2006) Brain nicotinic acetylcholine receptors: native subtypes and their relevance. Trends Pharmacol Sci 27: 482-491.
  • Zoli M., Moretti M., Zanardi A., McIntosh M.J., Clementi F., Gotti C. (2002) Identification of the nicotinic receptor subtypes expressed on dopaminergic terminals in the rat striatum. J. Neurosci. 22,8785-8789.
  • ChamptiauxN., Han Z-Y, Bessis A., Rossi F.M., Zoli M., Marubio L., McIntoshJ.M., Changeux J.-P. (2002) Distribution and pharmacology of alpha6-containing nicotinic acetylcholine receptors analysed with mutant mice. J. Neurosci, 22: 1208-1217.
  • Klink R., de Kerkhove d'Exaerde A., Zoli M., Changeux J.P. (2001) Molecular and physiological diversity of nicotinic acetylcholine receptors in the midbrain dopaminergic nuclei. J. Neurosci. 21: 1452-1463.
  • Zoli M., Jansson A., Sykova E., Agnati L.F., Fuxe K. (1999) Volume transmission in the CNS and its relevance for neuropsychopharmacology. Trends Pharmacol. Sci., 20: 142-150.
  • Zoli M.*, Picciotto M.R.*, Ferrari R., Cocchi D., Changeux J.-P. (1999) Increased neurodegeneration during aging in mice lacking high affinity nicotine receptors. EMBO J. 18, 1235-1244. *Equal contribution..
  • Zoli M., Léna C., Picciotto M.R., Changeux J.P. (1998) Identification of four classes of brain nicotinic receptors using beta2-mutant mice. J. Neurosci. 18, 4461-4472.
  • Picciotto M.R.*, Zoli M.*, Rimondini R., Léna C., Marubio L., Merlo Pich E., Fuxe K., Changeux J.-P. (1998) Acetylcholine receptors containing beta2 subunits are involved in the reinforcing properties of nicotine. Nature, 391, 173-177. *Equal contribution..
  • Picciotto M.R., Zoli M., Léna C., Bessis A., Lallemand Y., Le Novère N., Vincent P., Merlo Pich E., Brulet P., Changeux J.-P. (1995) Abnormal avoidance learning in mice lacking functional high-affinity nicotine receptor in the brain. Nature, 374, 65-67.
  • Zoli M., Le Novère N., Hill J.A. jr, Changeux J.P. (1995) Developmental regulation of nicotinic receptor subunit mRNAs in the rat central and peripheral nervous systems. J. Neurosci. 15, 1912-1939.

[Ultimo aggiornamento: 18/06/2019 13:30:49]